Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
This activity is supported by an educational grant from AstraZeneca.
April 2024
Cardiovascular risk factors and complications in patients with systemic lupus erythematosus with and without nephritis: A systematic review and meta-analysis
Lupus Sci Med 2024;11(1):e001152 DOI 10.1136/lupus-2024-001152
Patients with SLE and LN show increased risk of CV risk factors including diabetes mellitus, hypertension and hyperlipidaemia versus patients without nephritis.
Smith-specific regulatory T cells halt the progression of lupus nephritis
Nat Commun. 2024 Feb 6;15(1):899 DOI: 10.1038/s41467-024-45056-x
Compared with polyclonal mock-transduced regulatory T cells (Tregs), Smith(Sm)-Tregs potently suppress Sm-specific pro-inflammatory responses in vitro and suppress disease progression in a humanised mouse model of lupus nephritis.
Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: A multicentre, open-label, randomised controlled trial
Lancet Rheumatol 224;6(3):e168–77 DOI 10.1016/S2665-9913(23)00320-X
Mycophenolate mofetil (MMF) withdrawal was not significantly inferior to MMF maintenance through Week 60 in patients with SLE that had been treated with MMF for ≥1 year.